Physician profile
Shari L Sopher
NPI 1184650590
$2,957.96
in general payments reported to CMS, 2019-2025
31 companies · $774 in 2025
The $774 reported for 2025 was more than what 88% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $210 · 2022: $285 · 2023: $542 · 2024: $684 · 2025: $774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,978 · Entertainment: $22.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,978.10 |
| Entertainment | $22.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $559.33 | 2022-2025 | Veozah, Myrbetriq |
| Sage Therapeutics, LLC | $208.59 | 2024-2025 | Zurzuvae |
| Abbvie INC. | $196.68 | 2019-2023 | Lo Loestrin Fe |
| Amgen INC. | $159.04 | 2023-2025 | Evenity, Prolia |
| Renovia INC | $147.79 | 2020 | |
| Coopersurgical, INC. | $146.89 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Pfizer INC. | $139.03 | 2019-2025 | |
| Organon LLC | $129.66 | 2023-2025 | Nexplanon, Nuvaring |
| Bayer Healthcare Pharmaceuticals INC. | $117.52 | 2019-2025 | |
| Millicent US INC | $108.90 | 2019-2025 | Intrarosa, Femring |
| Ethicon US, LLC | $104.29 | 2024-2025 | Stratafix, Ethicon, Harmonic |
| Exeltis, USA INC. | $101.29 | 2024-2025 | Slynd |
| Therapeuticsmd, INC. | $94.38 | 2019-2022 | |
| Duchesnay USA Incorporated | $91.70 | 2019 | |
| Merck Sharp & Dohme LLC | $85.24 | 2019-2025 | Gardasil 9, Gardasil |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $75.13 | 2024-2025 | Aptima |
| Myriad Women'S Health, INC. | $75.05 | 2023 | Myrisk |
| Mayne Pharma Commercial LLC | $67.17 | 2023-2024 | |
| Supernus Pharmaceuticals, INC. | $47.86 | 2025 | Qelbree |
| Baxter Healthcare | $37.64 | 2019 | |
| Amag Pharmaceuticals, INC. | $36.17 | 2019 | |
| Meditrina | $33.04 | 2022-2025 | |
| Medtronic, INC. | $29.94 | 2025 | Truclear |
| Daiichi Sankyo INC. | $28.95 | 2024 | Injectafer |
| Provepharm INC. | $22.60 | 2024 | Bludigo |
| Evofem Biosciences, INC. | $21.76 | 2025 | Phexxi, Solosec, Phexx |
| Aspira Women'S Health INC | $21.23 | 2025 | Ova1 |
| Convatec INC. | $20.93 | 2025 | |
| Minerva Surgical, INC | $20.12 | 2025 | |
| Shield Therapeutics INC | $18.14 | 2023 | Accrufer |
| Aesculap, INC. | $11.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shari Sopher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.